Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.65 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.65 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415838 | 1.00 | MKNK1 (0.65) | MKNK1MKNK2ALPLMAP4K4MAP2K4 | |
| SCHEMBL4592444 | 0.84 | CYP11B1 (0.62) | MKNK1MKNK2ALPLMAP4K4CYP11B1 | |
| SCHEMBL23226759 | 0.82 | RXRA (0.61) | MAP2K4RHEB | |
| SCHEMBL22554086 | 0.81 | CYP11B1 (0.51) | MKNK1MKNK2ALPLMAP4K4CYP11B1 | |
| SCHEMBL22924782 | 0.80 | MKNK1 (0.73) | MKNK1MKNK2MAP4K4MAP2K4 | |
| SCHEMBL1436200 | 0.80 | ATM (0.65) | ALPLCYP11B1CYP11B2 | |
| SCHEMBL14926631 | 0.79 | CA1 (0.58) | MAP2K4 | |
| SCHEMBL7429971 | 0.79 | ALDH1A1 (0.52) | — | |
| SCHEMBL21392045 | 0.79 | CYP11B1 (0.53) | MKNK1MKNK2CYP11B1CYP11B2 | |
| SCHEMBL30416332 | 0.79 | CYP11B1 (0.53) | MKNK1MKNK2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | MKNK1 2780/4885MKNK2 2655/4885ALPL 1151/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | MKNK1 2780/4885MKNK2 2655/4885ALPL 1151/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MKNK1 2655/4885MKNK2 2513/4885ALPL 1080/4885 |
| US-11505547-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | MKNK1 2780/4885MKNK2 2655/4885ALPL 1151/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | MKNK1 2780/4885MKNK2 2655/4885ALPL 1151/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MKNK1 2655/4885MKNK2 2513/4885ALPL 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.